Last updated on March 2020

A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

Brief description of study

The study will investigate the efficacy and safety of an oral dose of AJM300 960 milligram (mg)/dose administered three times daily for 8 weeks in participants with active ulcerative colitis.

Clinical Study Identifier: NCT03531892

Find a site near you

Start Over

AJM300/CT3 trial site 76

Osakasayama, Japan
  Connect »